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Abstract: Data on the impact of the ketogenic diet (KD) on children’s growth remain controversial.
Here, we retrospectively investigated the occurrence of linear growth retardation in 34 children
(47% males; age range: 2−17 years) diagnosed with drug-resistant epilepsy (DRE; n = 14) or glucose
transporter type 1 deficiency syndrome (GLUT1-DS; n = 20) who had been treated with the KD
for 12 months. The general characteristics of children with and without growth retardation were
also compared. All participants received a full-calorie, traditional KD supplemented with vitamins,
minerals, and citrate. Most children (80%; 11/14 in the DRE subgroup and 16/20 in the GLUT1-DS
subgroup) treated with the KD did not show growth retardation at 12 months. Although participants
with and without delay of growth did not differ in terms of baseline clinical characteristics, dietary
prescriptions, or supplementation patterns, marked ketosis at 12 months tended to occur more
frequently in the latter group. Altogether, our results indicate that growth retardation may occur in a
minority of children treated with the KD. However, further research is required to identify children at
risk and to clarify how increased ketones levels may affect endocrine pathways regulating growth
during KD administration.
Keywords: ketogenic diet; growth; drug-resistant epilepsy; glucose transporter type 1 deficiency
syndrome; children
1. Introduction
The ketogenic diet (KD) is not only considered a valuable non-pharmacological therapeutic option
for children with drug-resistant epilepsy (DRE) [1] but it also represents the mainstay of treatment for
glucose transporter type 1 deficiency syndrome (GLUT1-DS, OMIM 606777) [2]. Patients with DRE
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should receive the KD for at least three months, after which it can be continued for several years if
symptoms subside (i.e., seizure reduction >50%) [3]. As far as subjects with GLUT1-DS are concerned,
the KD should be initiated with the expectation of a lifelong treatment [4].
KD requires constant nutritional monitoring over time both to ensure its effectiveness and to
reduce the likelihood of short- and long-term adverse effects [3]. Among the potential long-term
consequences, recent years have witnessed a remarkable interest on the possible effects of the KD on
children’s growth. Both retrospective [5,6] and prospective [7,8] investigations with follow-up periods
up to six months failed to identify a negative impact on growth percentiles. However, numerous
long-term studies reported a decrease of height [9] or weight and height [10–14] with the KD. Such
discrepancies clearly indicate that this issue deserves further scrutiny.
Data on factors that may affect the growth of children treated with the KD (e.g., ketosis or
nutrient adequacy) remain scarce. Peterson et al. [11] demonstrated that subjects with marked
ketosis were characterized by a significant decrease in height for age z-scores—an effect which was
not observed in presence of moderate ketosis. Spulber et al. [13] confirmed this observation in
a sample of 22 children—further reporting a negative correlation between growth rate and blood
beta-hydroxybutyrate (β-OHB) concentrations. With regard to nutrient adequacy, Neal et al. [12] failed
to identify significant associations between calorie or protein intake per se and the best fit of the line
slope for weight, height, or body mass index (BMI). In a retrospective analysis of food diaries collected
from 39 children treated with the KD, Nation et al. [6] showed that a caloric and protein intake <80%
of the recommended amount and a protein/energy ratio ≤1.4 g protein/100 kcal were associated with a
decrease in growth percentile. Notably, urinary ketosis levels were not predictive of children’s growth.
All of these studies have been conducted in patients with DRE. As far as GLUT1-DS is concerned,
only one case of a child with a growth deficit related to growth hormone (GH) deficiency has been
reported in the published literature [15]. Because patients with GLUT1-DS are expected to require a
lifelong assumption of the KD, data on its potential consequences on children’s growth in this clinical
population are eagerly awaited. Starting from these premises, we retrospectively investigated the
occurrence of linear growth retardation in 34 children diagnosed with DRE (n = 14) or GLUT1-DS
(n = 20) who had been treated with the KD for 12 months. The general characteristics of children with
and without growth retardation were also compared.
2. Materials and Methods
2.1. Ethical Approval
The study protocol complied with the tenets of the Helsinki Declaration and was approved by
the ethical committee of the Fondazione IRCCS Policlinico San Matteo of Pavia on 12 November 2018
(code number: 20180083746). All patients and/or caregivers provided their written informed consent.
2.2. Patients and Data Collection
Inclusion criteria were as follows: 1) age between 2 and 17 years; 2) diagnosis of DRE (defined as
unresponsiveness to at least two anticonvulsant medications) or GLUT1-DS; and 3) treatment with
KD for at least 12 months. All participants were consecutively enrolled at the Department of Child
Neuropsychiatry of the IRCCS Casimiro Mondino Foundation (Pavia, Italy) between 2008 and 2017.
Children with severe organ failure, thyroid disorders, or requiring enteral and parenteral nutrition were
excluded. The ambulation status of each child was analyzed in relation to age and physical activity.
Data were extracted from a retrospective review of clinical records and entered onto an electronic
database. Clinical, anthropometric, growth, and body composition parameters (i.e., weight, length or
height, BMI, height velocity, body fat percentage) of the study participants were collected at baseline
and at a 12-month follow-up. KD prescriptions and blood β-OHB concentrations were also recorded.
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2.3. Ketogenic Diet
Using a standardized approach [16], the Human Nutrition Research Center keto-team implemented
a non-fasting dietary protocol—which was uniformly applied in all of the study patients—characterized
by gradual increases of the ketogenic ratio. The usual caloric intake as well as food intolerances and
preferences were investigated using weekly food diaries. Energy prescriptions were tailored on each
patient’s specific requirements (based on basal energy expenditures measured by indirect calorimetry
and subsequently corrected for physical activity levels). KD plans with increasing ketogenic ratios
were adjusted at the individual level by an experienced dietician. Energy needs were reassessed
every 3 months in infants and children up to 10 years and every 6 months in adolescents. As far as
macronutrient composition is concerned, a minimum of 0.8−1 g of proteins from animal sources (e.g.,
eggs, milk, meat, poultry, and fish) were supplied per kilogram of body weight. All of the study
participants were prescribed sugar-free multivitamin and mineral supplements according to their age
and sex.
Oral citrates were also administered to prevent the formation of kidney stones. All patients were
started at home on a 1:1 ketogenic diet, with ketogenic ratios subsequently increased to 2:1, 3:1, or 4:1
in order to achieve blood β-OHB levels ≥2.0 mmol/L. Family members were instructed to monitor
blood β-OHB concentrations twice per day during the induction phase and report values by e-mail
to the study investigators. At follow-up visits, each patient underwent 1) measurements of fasting
blood ketones, 2) assessments of compliance to the prescribed diet regimen and supplement use, and
3) screening for potential adverse effects.
2.4. Anthropometric, Growth, and Body Composition Parameters
Anthropometric measurements taken by trained dieticians were used to define growth patterns
in accordance with standard procedures [17]. Body weight was measured with a digital scale to the
nearest 100 g with the subject wearing light clothes and without shoes. The height of children who
were able to stand was measured, with shoes removed, to the nearest 1 mm using a stadiometer. Supine
length was measured to the nearest 0.5 cm in all children who were unable to stand independently.
BMI was calculated as body weight in kilograms divided by height in meters squared. Anthropometric
measurements were plotted on standard growth charts (CDC 2000) [18] to calculate weight, height,
and BMI percentiles. The reference standards published by the Centers for Disease Control and
Prevention [18] were used to determine age- and sex-specific z-scores for weight, height, and BMI.
Changes in z-scores occurring between baseline and 12 months were calculated for height (∆ height
z-score), weight (∆ weight z-score), and BMI (∆ BMI z-score).
Height velocity (cm/years) was estimated from height measurements obtained immediately before
starting the diet and 12 months thereafter. Reference values for age and sex were obtained from
Tanner et al. [19]. In keeping with the methodology proposed by Nation et al. [6], standard growth
percentile charts were used to stratify patients into three growth pattern groups after 12 months of KD,
as follows: increased (Group-I), tracking (Group-T), and decreased (Group-D) linear growth. Group-I
consisted of children who showed an increased linear growth (i.e., crossing of one major percentile of
height in an upward fashion). Children with tracking linear growth (i.e., in line with their expected
percentile) were included in Group-T. Finally, Group-D consisted of children with a poor linear growth
(i.e., crossing of one major percentile of height in a downward fashion). Body composition was
measured with bioelectrical impedance analysis using a Handy 3000 device (DS-Medica, Milano,
Italy) with the child lying in the supine position. Electrode detectors were applied to the wrist and
ankle. Percent fat mass (% FM) was estimated from raw impedance values using the equation of
Houtkooper et al. [20].
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2.5. Statistical Analysis
Continuous variables were expressed as medians and interquartile ranges (IQRs) and compared
across the three growth groups using the non-parametric Kruskall-Wallis test followed by post hoc
non-parametric sign tests with the Bonferroni’s correction. Categorical variables were analyzed with
the chi-squared test or the Fisher’s exact test, as appropriate. Associations between changes in height
z-scores at 12 months and other continuous variables were tested with the Spearman’s correlation
coefficient (%). All calculations were performed with STATA/SE®for Windows, version 15 (StataCorp,
College Station, TX, USA). Two-tailed p values <0.05 were considered statistically significant.
3. Results
Table 1 shows the baseline characteristics of the entire study sample as well as separately for
patients with DRE and GLUT1-DS. Thirty-four children (16 male and 18 female) were included in the
study. DRE was diagnosed in 14 children, whereas the remaining 20 had GLUT1-DS. In the entire
sample, the median age at diagnosis was 7.5 (4.0–10.0) years and the age at the beginning of KD ranged
from 2 to 15 years (16 children were aged between 2 and 6 years, 10 between 7 and 10 years, and 8
between 11 and 17 years).
Patients with GLUT1-DS were diagnosed at an older age (median= 8.5 years; IQR = 5.0–10.0 years)
than those with DRE (median = 4.0 years; IQR = 1.0–7.5 years; p = 0.041) and began dietary treatment
earlier after diagnosis (median interval = 0.0 years; IQR = 0.0–1.0 years versus median = 4.7 years;
IQR = 3.5–6.5 years, respectively, p< 0.001)—an expected finding being KD the only available treatment
for GLUT1-DS.
All patients were in the pre-pubertal phase, with the exception of three subjects (1 with DRE and
2 with GLUT1-DS). There were significant differences in terms of anti-epileptic drugs (AEDs) and
ambulation between the two groups. Specifically, all patients with GLUT1-DS were able to ambulate
and none of them was taking AEDs. Ten patients with DRE were on multiple anti-epileptic drugs
(AEDs) and their pharmacological treatment was not modified throughout the study. Moreover, five of
them were unable to ambulate.
Table 2 shows the changes in growth status and body composition after 12 months of KD in
the entire sample as well as separately for patients with DRE and GLUT1-DS. At baseline, there
were no significant differences in median height z-scores between patients with DRE and GLUT1-DS
(median = −0.4; IQR = 1.5−0.2 versus median = −0.7; IQR = −1.3−0.2, respectively, p = 0.675). No
significant changes in all parameters emerged for both groups. Specifically, after 12 months of KD,
the median height z-score did not change significantly from baseline both in patients with DRE
(median = −0.4; IQR = −1.5–0.2 versus median = −0.4; IQR = −2.1−0.6; p > 0.90) and GLUT1-DS
(median = −0.7; IQR = −1.3–0.2 versus median = −0.6; IQR = −1.4−0.3; p > 0.90). Based on these
observations, all of the study patients were grouped together for analysis of growth patterns regardless
of their underlying diagnosis.
Group-I consisted of six children (2 male and 4 female) of whom 3 had GLUT1-DS. Three children
were aged between 2 and 6 years and 3 between 7 and 10 years. One child was unable to ambulate.
Group-T included 21 patients (11 male and 10 female) of whom 13 had GLUT1-DS. Eight children were
aged between 2 and 6 years, 5 between 7 and 10 years, and 8 between 11 and 17 years. Three children
were unable to ambulate. This group comprised three post-pubertal children. Finally, Group-D
consisted of seven children (3 male and 4 female) of whom 4 had GLUT1-DS. Five children were
aged between 2 and 6 years and 2 between 7 and 10 years. One child was unable to ambulate. The
baseline characteristics of the three growth groups are summarized in Table 3. The three groups did
not differ significantly in terms of clinical characteristics at baseline, the only exception being age
at diagnosis (p = 0.028), which was lower in Group-D (median = 5 years; IQR = 3−6 years) than in
Group-T (median = 9.0 years; IQR = 8−10 years; p = 0.041).
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Table 1. Baseline characteristic of the entire sample and of DRE and GLUT1-DS patients.
ENTIRE SAMPLE DRE GLUT1-DS p
n = 34 n = 14 n = 20
Sex (male/female) 16/18 7/7 9/11 >0.90
Age at diagnosis (years) 7.5 (4.0–10.0) 4.0 (1.0–7.5) 8.5 (5.0–10.0) 0.041
Age at ketogenic diet initiation (years) 8.0 (3.0–10.0) 4.0 (2.0–10.0) 9.0 (5.0–10.5) 0.310
Interval between diagnosis and
ketogenic diet initiation (years)
0.5
(0–4.2)
4.7
(3.5–6.5)
0.0
(0.0–1.0) <0.001
Puberty (yes/no) 3/34 1/13 2/18 >0.90
Number of AEDs <0.001
None 21/34 1/14 20/20
1 3/34 3/14 0/20
>1 10/34 10/14 0/20
Ambulation 0.007
Yes 29/34 9/14 20/20
No 5/34 5/14 0/20
Data are reported as counts, medians, and interquartile ranges, as appropriate. Abbreviation: DRE, drug resistant
epilepsy; GLUT1-DS, glucose transporter type 1 deficiency syndrome; AEDs, anti-epileptic drugs; Significant
p values are marked in bold (p < 0.05) for comparison between DRE and GLUT1-DS patients.
Table 2. Changes in growth status and body composition after 12 months on KD in the entire sample
and in DRE and GLUT1-DS patients *.
ENTIRE SAMPLE DRE GLUT1-DS
n = 34 n = 14 n = 20
Baseline 12 Months Baseline 12 Months Baseline 12 Months
Height
(cm)
118.5
(95.0–143.0)
124.5
(104.0–148.0)
104.5
(92.5–137.5)
111.5
(99.0–139.0)
125.3
(107.0–148.0)
130.0
(113.0–153.5)
Height z-score −0.6(−1.4–0.2)
−0.6
(−1.8–0.5)
−0.4
(−1.5–0.2)
−0.4
(−2.1–0.6)
−0.7
(−1.3–0.2)
−0.6
(−1.4–0.3)
Weight
(kg)
22.3
(15.0–37.7)
23.3
(17.7–42.1)
20.3
(11.6–35.6)
21.9
(13.6–34.4)
22.6
(16.8–40.1)
24.4
(18.9–46.5)
Weight z-score −0.4(−1.3–0.6)
−0.4
(−1.6–0.5)
−0.3
(−1.0–1.1)
−0.3
(−1.9–1.1)
−0.4
(−1.6–0.5)
−0.4
(−1.5–0.2)
BMI
(kg/m2)
16.6
(15.3–19.4)
16.9
(15.0–18.0)
16.7
(15.0–19.4)
16.7
(14.6–18.0)
16.6
(15.5–18.6)
16.9
(15.0–18.1)
BMI z-score 0.2(−1.0–0.9)
−0.1
(−0.8–1.0)
0.1
(−1.0–1.0)
−0.1
(−0.8–1.1)
0.2
(−0.9–0.8)
−0.1
(−0.9–1.0)
FAT
(% weight)
32.4
(30.1–34.3)
29.9
(27.7–33.0)
32.9
(31.9–35.6)
30.8
(27.8–36.0)
30.9
(27.4–33.4)
29.2
(26.3–31.8)
Data are reported as medians and interquartile ranges. Abbreviation: DRE, drug resistant epilepsy; GLUT1-DS,
glucose transporter type 1 deficiency syndrome; BMI, body mass index; FAT, fat free mass. * There were no
significant differences between baseline and 12 months in each study group.
A lower percentage of energy intake as carbohydrates was evident for Group-T (6.7%;
IQR = 6.5−7.1%) compared with Group-I (4.4%; IQR 3.8−6.2%, p = 0.043).
The adherence to the prescribed dietary intakes was based on information provided by parents
during control visits or through emails. Episodes of food refusal or incomplete meal consumption
were reported for 11 of the 34 study patients, with the following distribution: one case out of 6 in
Group-I, 7 cases out of 21 in Group-T, and 3 cases out of 7 in Group-D. No other adverse effects were
observed throughout the study period.
Fasting β-OHB blood levels at 12 months did not differ significantly in the three study groups,
being 1.8 mmol/L (IQR = 1.2–2.7 mmol/L) in Group-I, 2.4 mmol/L (IQR = 1.5–3.2 mmol/L) in Group-T,
and 4.1 mmol/L (IQR = 1.9–6.1 mmol/L) in Group-D (p < 0.199). In the entire sample, a moderate
inverse correlation was evident between fasting β-OHB blood levels at 12 months and the height
z-score (% = −0.35; p = 0.04).
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Table 3. Comparison of baseline characteristics in the three growth groups.
Group-I
(Increase)
Group-T
(Track)
Group-D
(Decrease) p
n = 6 n = 21 n = 7
Sex (male/female) 2/4 11/10 3/4
Age at diagnosis (years) 2.0 (2.0–7.0) 9.0 (8.0–10.0) 5.0 (3.0–6.0) 0.0280.041 **
Age at ketogenic diet initiation (years) 5.5 (2.0–10.0) 9.0 (5.0–11.0) 5.0 (2.0–7.0) 0.084
Interval between diagnosis and
ketogenic diet initiation (years) 1 (0–3) 0 (0–5) 0.5 (0–1) 0.727
Puberty (yes/no) 0/6 3/18 0/7 0.754
Disease 0.889
Drug-resistant epilepsy 3/6 8/21 3/7
GLUT1-DS 3/6 13/21 4/7
Number of AEDs 0.750
None 3/6 14/21 4/7
1 1/6 1/21 1/7
>1 2/6 6/21 2/7
Ambulation >0.90
Yes 5/6 18/21 6/7
No 1/6 3/21 1/7
Data are reported as counts, medians, and interquartile ranges, as appropriate. Abbreviation: GLUT1-DS, glucose
transporter type 1 deficiency syndrome; AEDs, anti-epileptic drugs. Significant p values are marked in bold. The
first p refers to three-group comparisons, being calculated from the non-parametric Kruskal–Wallis test. In the
event of this P value being statistically significant (i.e., p < 0.05), the second p value indicates significant pairwise
comparisons. Comparisons between ** Group-D and Group-T.
Table 4 shows the KD composition—in terms of energy and macronutrients—in three growth
groups as well as the WHO recommendations for age ranges reflected in the study population.
Table 4. Ketogenic diet composition—in terms of energy and macronutrients—in the three
growth groups.
WHO
Recommendations
Group-I
(Increase)
Group-T
(Track)
Group-D
(Decrease) p
n = 6 n = 21 n = 7
Energy intake (kcal/day) 1088–2720 a 1235.5(788.0–1757.0)
1671.0
(1407.0–1805.0)
1282.0
(1150.0–1380.0) 0.085
Energy intake (kcal/kg) 51–82 a 61.3 (51.2–81.2) 54.4 (41.5–66.7) 72.7 (62.5–95.8) 0.066
Carbohydrate
(% energy) 55–75
b 6.7 (6.5–7.1) 4.4 (3.8–6.2) 6.6 (4.0–9.9) 0.0280.043 *
Protein (% energy) 3.7–5.5 c 5.6 (5.4–7.1) 7.8 (6.5–8.5) 8.3 (6.5–8.7) 0.053
Protein g/100 kcal 0.9–1.4 c 1.4 (1.4–1.8) 2.0 (1.6–2.1) 2.1 (1.6–2.2) 0.073
Fat (% energy) 25–35 d 87.5 (87.1–87.5) 87.4 (87.2–87.5) 86.5 (79.1–87.4) 0.100
Saturated fat
(% energy) 8
d 21.2 (17.6–29.0) 31.3 (21.2–34.1) 25.7 (23.7–33.9) 0.452
Monounsaturated fat (% energy) 6–16 d§ 21.7 (20.4–26.4) 20.4 (16.1–24.5) 26.0 (24.5–29.9) 0.067
Polyunsaturated fat (% energy) 11 d 5.5 (4.1–8.1) 5.7 (4.7–8.3) 8.6 (5.7–9.3) 0.368
Cholesterol (mg/day) <300 d
164.3
(107.3–217.2)
262.8
(137.1–347.5)
207.3
(179.0–289.8) 0.468
Fiber (g/day) 25 e 4.8 (3.6–10.2) 6.8 (4.7–9.3) 7.2 (5.8–8.3) 0.751
Data are reported as medians and interquartile ranges. Significant p values are marked in bold. The first p refers
to three-group comparisons, being calculated from the non-parametric Kruskal–Wallis test. In the event of this p
value being statistically significant (i.e., p < 0.05), the second p value indicates significant pairwise comparisons.
Comparisons between * Group-I and Group-T. a [21]; b [22]; c [23], calculations were performed from values for protein
and energy requirements (protein (g/kg) × 4)/ energy (kcal/kg). Safe protein: energy ratio for an individual calculated from
protein and energy requirement values; d [24]; e [25]; § Calculated as difference between Total fat – Saturated Fat Acids – Total
Polyunsaturated fat.
Table 5 depicts the anthropometric and growth parameters (expressed as z-scores) observed in
the three growth groups at baseline and after 12 months of KD. At baseline, there were no significant
intergroup differences in terms of height, weight, or BMI z-scores. At 12 months, height (median = −1.4;
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IQR = −2.3–−0.6 versus median = 0.6; IQR = 0.3–0.9, respectively; p = 0.045) and growth velocity
(median = −2.9; IQR = −3.6–−2.2 versus median = 2.2; IQR −0.2–4.2, respectively; p = 0.019) z-scores
were significantly lower in Group-D than in Group-I.
Table 5. Comparison between anthropometric and growth pattern characteristics (given as z-scores) of
the three growth groups at baseline and after 12 months of ketogenic diet.
Group-I
(Increase)
Group-T
(Track)
Group-D
(Decrease) p
n = 6 n = 21 n = 7
BASELINE
Height −0.4 (−1.1–0.3) −0.6 (−1.5–0.2) −0.8 (−1.0–0.2) 0.974
Weight −0.9 (−1.8–0.1) −0.1 (−1.1–1.1) −0.6 (−1.3–0.3) 0.383
BMI −0.9 (−1.4– −0.7) 0.3 (−0.5–1.3) 0.3 (−1.0–0.7) 0.256
FAT (% weight) 32.7 (27.9–36.8) 32.5 (30.1–34.3) 30.9 (30.4–30.9) 0.710
12 MONTHS
Height 0.6 (0.3–0.9) −0.5 (−1.6–0.3) −1.4 (−2.3– −0.6) 0.0200.045 ***
Weight 0.1 (−0.4–1.4) −0.4 (−1.6–0.8) −1.3 (−3.0– −0.1) 0.227
BMI −0.4 (−0.7–1.2) 0.0 (−0.7–1.1) 0.3 (−1.6–0.6) 0.685
FAT (% weight) 34.1 (30.5–36.2) 28.4 (26.6–31.1) 31.4 (29.2–32.7) 0.110
Growth velocity 2.2 (−0.2–4.2) −0.4 (−1.8–0.9) −2.9 (−3.6– −2.2)
0.002
0.010 **
0.019 ***
∆ height 0.9 (0.8–1.6) 0.0 (−0.1–0.1) −1.1 (−1.2–0.3)
∆ weight 1.5 (0.5–2.5) −0.3 (−0.7–0.1) −0.3 (−0.7– −0.3)
0.002
0.003 *
0.008 ***
∆ BMI 0.7 (0.1–1.3) −0.3 (−0.6–0) −0.1 (−0.5–0.1) 0.065
∆ FAT (% weight) −2.4 (−3.6–1.4) −1.3 (−5.4–0.3) −0.2 (−0.7–0.0) 0.540
Data are reported as medians and interquartile ranges. Abbreviation: BMI, body mass index; FAT, fat free mass.
Significant p values are marked in bold. The first p refers to three-group comparisons, being calculated from
the non-parametric Kruskal–Wallis test. In the event of this p value being statistically significant (i.e., p < 0.05),
the second p value indicates significant pairwise comparisons. Comparisons between * Group-I and Group-T, **
Group-D and Group-T, *** Group-D and Group-I.
After 12 months of KD, weight z-score was found to be more markedly impaired in Groups-D and
-T than in Group-I—as shown by the following significant intergroup differences in ∆ weight z-scores:
Group-I (median = 1.5; IQR = 0.5–2.5) versus Group-T (median = −0.3; IQR = −0.7–0.1; p = 0.003) or
Group-D (median = −0.3; IQR = −0.7–−0.3; p = 0.008).
Fat mass percentage at baseline did not differ significantly in the three groups [Group-I
(median = 32.5%; IQR = 30.1–34.3%), Group-T (median = 32.7%; IQR = 27.9−36.8%), and Group-D
(median = 30.9%; IQR = 30.4–30.9%; p = 0.71)] and did not appreciably change at 12 months.
In the entire sample at 12 months, there was a moderate positive correlation between height
z-scores and weight z-scores (% = 0.580; p <0.001).
Detailed information on the three growth pattern subgroups are presented separately for patients
with DRE and GLUT1-DS in Supplementary Tables S1–S3.
4. Discussion
In this retrospective study, we sought to investigate the linear growth of children who remained on
KD for 12 months. The results revealed that most of our patients (80%) maintained or even improved
their growth at 12-month follow-up. Notably, this observation was consistent in children diagnosed
with both DRE (of whom 11 out of 14 maintained or improved growth) and GLUT1-DS (among whom
16 out of 20 maintained or improved growth). Our findings are in accordance with those obtained in
recent long-term follow-up studies. Wibisono et al. [26] reported their 10-year single-center experience
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with KD in Australia. Data from 33 children who had their height measured revealed that—during
a 24-month period—height tracked along percentiles in 16 cases (48%). Increased and decreased
height—by at least one standard deviation on percentile growth curves—was observed in seven (21%)
and ten (30%) cases, respectively. Consequently, approximately 70% of their patients maintained
or improved their linear growth pattern. In a prospective study, Lambrechts et al. [27] reported
that 30% of their patients showed a growth deceleration after two years on KD. An investigation
conducted in 50 Austrian children (mean age: 4.44 ± 3.55 years) with DRE, treated for 1.18 ± 1.06 years
(minimum–maximum: 0.06−3.87 years) revealed that the frequency of growth retardation was as low
as 6% [28].
Taken together, published evidence and our current data consistently indicate that growth
retardation may occur in a minority of patients treated with the KD. From a clinical standpoint, it
would be helpful to identify children at higher risk of poor growth before starting the KD. In an effort
to address this issue, we compared the general characteristics of patients showing different growth
patterns. However, Group-D was significantly different from other groups only in terms of age at
diagnosis (which was found to be lower in this group compared to the Group-T). Because the interval
between diagnosis and KD initiation did not show significant intergroup differences, the length of
time during which the patient remained on a balanced diet cannot be a factor explaining the observed
growth differences. Moreover, dietary prescriptions, supplementation patterns, and follow-up periods
did not differ significantly in the three growth groups.
Potential causes of poor growth in children on the KD include inadequate intakes of energy and
protein (compared with recommended values), the effects of the underlying diseases and treatments,
acidosis/ketosis and related endocrine changes.
In a retrospective study conducted in 21 children (mean age: 7.9 ± 3.8 years), Williams et al. [10]
reported a significant decrease in height and weight percentiles after two years on a classical KD.
A prospective cohort study conducted in 237 children (age range: from 2 months to 9 years and
10 months) reported a small decrease in height z-scores in the first six months on a KD followed
by larger changes at two years [29]. These studies were based on traditional ketogenic dietary
regimens characterized by calorie restriction (75–85% of recommended daily energy) to achieve
ketosis [30,31]. Therefore, their findings in relation to growth may have originated from inadequate
calorie prescriptions. Calorie restriction for induction of ketosis is no longer used by most centers
belonging to the International Ketogenic Diet Study Group [3]. In keeping with current guidelines,
our study population started their KD regimen at full calorie (based on actual measures of energy
expenditure which were subsequently fine-tuned at control visits)—an approach which may have
prevented the decline in linear growth observed in earlier studies.
To achieve a level of ketosis adequate for seizure control (in epilepsy) and for ketone use as an
alternative fuel for brain metabolism (in GLUT1-DS), very low amounts of carbohydrates, adequate
amounts of protein, and very high amounts of fat must be prescribed in a rigidly controlled ratio
(ketogenic ratio)—resulting in a highly unbalanced diet compared to WHO recommendations for
children and adolescents [21–25]. This kind of diet should be used only in presence of a medical
condition that can be improved or cured by this regimen under a strict medical monitoring according
to International Guidelines [3].
The maintenance of the ketogenic ratio limits the amount of proteins that can be included in
the classical KD—although an amount of 0.8–1 g/kg body weight is generally provided. However,
the amount of proteins needs to be carefully evaluated according to energy requirements in terms
of protein-to-energy ratio [23]—an index of dietary quality particularly in the context of marginal
food intake [23]. This topic was analyzed for the first time by Nation et al. [6], who demonstrated
that a protein-to-energy ratio greater than 1.5 g protein/100 kcal is paramount to achieve satisfactory
linear growth patterns in 35 children (age range: from 8 months to 16.5 years) treated with the KD
for at least six months. All of the patients in the current study were prescribed a protein amount
(expressed as percentage of total daily calories or as protein-to-energy ratio) in line with the WHO
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recommendations and the “appropriate ratio” according to Nation et al. [6]. We therefore believe that
factors other than low energy or protein prescription should be considered to explain the decline in
linear growth observed in some patients.
Growth patterns in children on KD may be influenced by the underlying disease as well as
the presence of comorbidities and concomitant drug treatments. Patients with DRE may show
suboptimal growth patterns even before the initiation of KD because of endocrine dysfunction or
the use of multiple AEDs [32–34]. However, AEDs utilization did not show significant intergroup
differences in our study. A direct comparison of our findings with those of other recent studies [9,13]
is problematic owing to differences in the study population. Of the 22 children with growth deficit
described by Spulber et al. [13], 21 had mental retardation, 14 autism spectrum disorder and nine were
non-ambulatory; moreover, all of the children had been on long-term treatment with seven AEDs
before KD implementation. Similarly, among the 15 children studied by Grouleau et al. [9] only those
affected by cerebral palsy showed a −0.7 decline in height z-scores over a 15-month follow-up period.
A single case of growth retardation related to GH deficiency has been reported in GLUT1-DS [15],
making the exact incidence of poor growth difficult to estimate in this condition.
In the current study, growth deficit was identified in only 20% of the study participants, without
significant differences between children with DRE and GLUT1-DS. With the exception of one child
in Group-D who was non-ambulatory, the main characteristic of our patients with delayed growth
was a reduction in weight z-score, suggesting that periods of inadequate caloric intake may have
occurred notwithstanding an adequate calorie prescription based on actual needs. A high-fat KD may
be unpalatable for some subjects and can result in occasional food refusal, which was more frequently
observed in Group-D (3 out of 7 children). However, a reduction in z-score was also observed in the
Group-T. More interestingly, a trend toward higher ketone levels was evident in Group-D, albeit not
significantly so (possibly because of the small sample size).
A chronic systemic reduction of pH is known to impair growth [35] and KD may cause a
persistent—albeit generally mild or clinically asymptomatic—metabolic acidosis. In this scenario,
elevated levels of ketones induced by diets with high (4:1 and 3:1) ketogenic ratios may be another
potential cause of poor growth. Accordingly, a negative correlation between height velocity and
ketone levels has been reported for the first time by Peterson et al. [11] using a semi-quantitative urine
dipstick test. Their results revealed that after 12 months on KD subjects with high urinary ketone
levels (80–120 mg/dL) were characterized by lower height z-scores than those with moderate ketosis
(<80 mg/dL). Spulber et al. [13] confirmed and expanded this observation by showing a negative
correlation between blood β-OHB levels and both growth velocity and insulin growth factor-1 (IGF-1).
IGF-1 is the key effector peptide for childhood linear growth in response to stimulation by growth
hormone [36] and has been found to be decreased in starvation [37]. Fraser et al. [38] reported a 46%
decrease in serum IGF-1 levels following seven days of a ketogenic diet that restricted CHO to less than
40 g/day while providing adequate energy and protein intake. It is thus possible that the starvation-like
metabolic state induced by KD may reduce IGF-1 levels or decrease their bioavailability [9,13]. In a
study conducted in 28 Swedish children, the Modified Atkins Diet (MAD—an alternative dietary
treatment for epilepsy characterized by a low ketogenic ratio (0.8/1:1)—has been shown to induce
lower levels of ketosis, which did not affect growth or IGF-1 levels at two years [39]. In line with this
report [39], our dietary protocol routinely included oral citrates which—besides their affect against
kidney stone formation—may also mitigate acidosis and its adverse effects on growth. In clinical
practice, it is advisable to implement a close growth monitoring in all children with a high level of
ketosis, aimed at eventually reducing the ketogenic ratio to lower values (albeit maintaining their
compatibility with seizure symptoms control).
The caveats of our investigation include its retrospective design and the limited sample size.
These limitations notwithstanding, our study describes for the first time the growth patterns of children
with GLUT1-DS who had been treated with the KD. Importantly, most of our patients were able to
maintain or improve their growth patterns. We speculate that our promising results may be ascribed
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to an accurate assessment of energy needs (obtained by repeated measurements of resting energy
expenditure and a thorough assessment of daily physical activity levels), an adequate protein-to-energy
ratio according to WHO recommendations, as well as to the continuing support offered to caregivers
involved in the management of KD. Moreover, the routine supplementation of oral citrate may have
mitigated the detrimental impact of chronic metabolic acidosis. However, more research is required
to identify children at higher risk of growth delay. In addition, the potential role played by high
ketone levels on altered IGF-1 signaling in influencing linear growth of children on KD needs further
exploration. Under these circumstances, a more in-depth endocrine evaluation is advisable for all
children who show evidence of growth retardation while on the KD.
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Table S1: Baseline characteristics of patients with DRE and GLUT1-DS presented separately and in relation
to the three different patterns of growth, Table S2: Ketogenic diet composition—in terms of energy and
macronutrients—of patients with DRE and GLUT1-DS presented separately, Table S3: Anthropometric and growth
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of ketogenic diet in patients with DRE and GLUT1-DS presented separately.
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